Post-ERCP Pancreatitis - Prophylactic Measures Implementation Study (PEP-PROMIS)
NCT ID: NCT07244432
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
1000 participants
OBSERVATIONAL
2025-12-01
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
ERCP is a common procedure used to treat problems in the bile ducts and pancreas. Although generally safe, it sometimes leads to PEP, which is the most frequent and potentially serious complication. Monitoring the rate of PEP helps doctors evaluate the overall quality of ERCP procedures, since patient safety is an important part of quality care.
The study will also look at how well hospitals follow current prevention guidelines from two major professional organizations-the European Society of Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE)-and how these prevention methods affect the risk of PEP. This information will help identify how closely real-world practice follows recommended preventive measures and provide new data about PEP rates in the region.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
NCT05310409
ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?
NCT02602574
Patient-reported Outcome Scale in Acute Pancreatitis
NCT03650062
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
NCT04770857
Post ERCP Pancreatitis Prevention in Average Risk Patients
NCT01784445
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Consecutive adult patients with native papilla undergoing ERCP at participating centers.
Consecutive adult patients undergoing first endoscopic retrograde cholangiopancreatography (ERCP) or repeat ERCP after a previous failed cannulation attempt who have provided signed informed consent will be included. Patients will be excluded if they have a history of papillotomy, papilla dilation, or sphincteroplasty; if the rendezvous cannulation technique is used; if they show insufficient cooperation preventing cannulation; or if the ERCP is terminated before cannulation due to sedation- or anesthesia-related complications. Additional exclusion criteria include failure to reach the major or minor papilla (for example, due to duodenal stenosis), acute biliary pancreatitis, or altered anatomy preventing access to the papilla with a standard duodenoscope (such as Roux-en-Y reconstruction). The standard ERCP procedure will be performed under analgosedation or general anesthesia, depending on the patient's condition and the institutional protocol.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age at least 18 years at the time of ERCP.
* Signed informed consent.
Exclusion Criteria
* Rendez-vous cannulation technique.
* ERCP not performed due to insufficient patient cooperation.
* ERCP terminated before cannulation due to sedation/anesthesia-related complications.
* Failure to reach the Vater's or minor papilla (e.g. duodenal stenosis).
* Acute biliary pancreatitis.
* Altered anatomy that prevents reaching the papilla with a standard duodenoscope (e.g. Roux-en-Y).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Branislav Kuncak
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Branislav Kuncak
Head of Gastroenterology, Principal Investigator, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan Martinek, Prof, MD, Ph.D
Role: STUDY_CHAIR
Gastroenterology, St. Anne´s University Hospital, Brno, Czech Republic
Branislav Kunčak, MUDr.
Role: PRINCIPAL_INVESTIGATOR
St. Michael´s University Hospital and Slovak Health University, Bratislava, Slovakia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NSM-BA-PEP-PROMIS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.